Growing NBRx on a Flat Media Budget

How an established prescription brand grew sales 23% on flat media spend

Overview

An established prescription brand grew its sales over three years without increasing media investment. Sales rose 23% in the most recent year and grew steadily across the full period. A marketing mix model credits the media with a return of about 10x on brand sales, with a high reading of 25x.

RoseRx carried that media into a compliant patient conversation. Those conversations also gave the commercial team a direct read on what patients and physicians were asking.

The problem

For this brand, most of the sale happens where ad clicks cannot follow. A patient sees an ad, books a physician visit, and fills a prescription at a pharmacy. The brand sees a sales number months later with no campaign attached.

Ad platforms optimize on impressions and clicks because that is as far as they can see and the offline sale is never properly attributed. Even same-month reporting cannot tell a commercial team whether media moved those sales.

What RoseRx did

Every media placement carried a call to action into a RoseRx conversation built on the brand's MLR-approved content. Patients who responded reached the agent directly and got an on-brand answer to the question they asked. The agent's job was to inform the patient before the physician visit.

Because every media path ran through RoseRx, the model measures sales against a known route.

RoseRx also measured actions well past the click. A patient signaling intent to book an appointment counts as a conversion event. Read alongside the content of the conversations, that shows which messaging moved patients rather than which ad earned a click.

What the data shows

Growth is measured in IQVIA data across three years. Brand sales grew about 23% in the most recent year. The rate held across the full period of three years.

Media efficiency

The growth came as the media budget the brand was already running.

The marketing mix model separates media from baseline growth and seasonality. It allows for the two to four month delay between an ad and a pharmacy re-order. The model credits media with about 4% of brand sales, a payback near 25x. Under the most conservative reading, the same media pays back about 3x. The best-evidenced channel is significant at p < 0.001.

Commercial evidence

Every conversation is a record of what patients and physicians want to know. The agent runs on approved content and sits at the point of intent, so it captures questions in the patient's own words and the path they take to a decision, including where they hesitate and where they leave.

That gives the brand two things: It shows the concerns patients and HCPs raise, and whether the approved content answers them. It counts those patterns at scale, so the commercial team can see what comes up most, where the content has gaps, and how demand is shifting. The marketing mix analysis adds the channel-level read on which media did the work.

Where this applies

This case study holds for any brand whose sales complete offline while its media is scored on same-month clicks. Routing that media into a RoseRx conversation answers the patient while attention is on the brand and keeps approved information in front of them. The result is more sales from the same spend and a clearer read on what produced them.

Summary

RoseRx-connected media is associated with sustained, IQVIA-measured sales growth and a return that pays back on every reading the model tested. For a comparable brand, the same approach turns existing media into measured sales and a standing read on what patients and physicians want.